ResultsIQ

ResultsIQ › Latest results › Themis Medicare Limited

Themis Medicare Limited Q3 FY26 results deck summary

NSE: THEMISMED · BSE: 530199

Results deck of 13 Feb 2026, summarised by AI from the filing.

Q3 FY26 net revenue ₹90.13 cr, PAT ₹10.09 cr; API business more than doubled YoY despite business disruption.

Key takeaways

  1. Guidance No forward guidance was given; management expects a positive development on the regulatory review soon.
  2. Change Q3 FY26 turned profitable versus Q2 FY26, with PAT ₹10.09 cr against ₹(3.62) cr.
  3. Driver API business more than doubled YoY, partially offset by softness in formulations.
  4. Risk Disruption in a significant line of business continued through the quarter.

Original filing on BSE

Themis Medicare Limited Q1 FY27 results

As filed: Revenue ₹87.0 cr (−11% year on year), EBITDA −₹52.4 cr, PAT ₹24.6 cr, EBITDA margin -60.3% (−1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹76.5 cr (+6% year on year), EBITDA ₹3.8 cr, PAT ₹8.9 cr, EBITDA margin 4.9% (+1,000 bps). Score 56 of 100, In line with trend. Revenue growth was in line with the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 172% of PBT. Tax rate 8%. Revenue fell 15% from last quarter. Share price after the results: +0.4% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹90.1 cr (−4% year on year), EBITDA ₹9.8 cr (+9% year on year), PAT ₹10.1 cr (+44% year on year), EBITDA margin 10.9% (+130 bps). Score 49 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit before exceptional items growth was above it. EBITDA margin rose 130 bps year on year. Other income 26% of PBT. Tax rate 6%. Profit before exceptional items rose ₹1.7 cr on a year ago, more than the ₹1.0 cr it added the year before. Share price after the results: −14.1% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹78.0 cr (−33% year on year), EBITDA −₹2.0 cr (−113% year on year), PAT −₹4.0 cr (−129% year on year), EBITDA margin -2.6% (−1,000 bps). Score 19 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 20% from last quarter. Share price after the results: −16.3% in 29 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹98.0 cr (−20% year on year), EBITDA −₹10.0 cr (−136% year on year), PAT −₹14.0 cr (−156% year on year), EBITDA margin -10.2% (−1,000 bps). Score 18 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Share price after the results: −5.8% in 28 days (Nifty 500: −0.9%).
  • Q4 FY25: Revenue ₹72.0 cr (−27% year on year), EBITDA −₹6.0 cr (−167% year on year), PAT −₹10.0 cr (−243% year on year), EBITDA margin -8.3% (−1,000 bps). Score 4 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Revenue fell 23% from last quarter. Share price after the results: −19.0% in 30 days (Nifty 500: +0.8%).
  • Q3 FY25: Revenue ₹94.0 cr (+13% year on year), EBITDA ₹9.0 cr (+13% year on year), PAT ₹1.0 cr (−86% year on year), EBITDA margin 9.6% (−6 bps). Score 39 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well below it. EBITDA margin was flat year on year. Consolidated profit -86% but standalone +50%. Revenue fell 20% from last quarter.
  • Q2 FY25: Revenue ₹117 cr (+11% year on year), EBITDA ₹16.0 cr (+23% year on year), PAT ₹14.0 cr (+27% year on year), EBITDA margin 13.7% (+129 bps). Score 64 of 100, In line with trend. EBITDA margin rose 129 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 5% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Themis Medicare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.